- Home
- BXSL vs NUVL Comparison
BXSL vs NUVL Comparison
Compare BXSL & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BXSL
- NUVL
- Stock Information
- Founded
- BXSL 2018
- NUVL 2017
- Country
- BXSL United States
- NUVL United States
- Employees
- BXSL N/A
- NUVL N/A
- Industry
- BXSL Trusts Except Educational Religious and Charitable
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- BXSL Finance
- NUVL Health Care
- Exchange
- BXSL Nasdaq
- NUVL Nasdaq
- Market Cap
- BXSL 7.3B
- NUVL 5.8B
- IPO Year
- BXSL N/A
- NUVL 2021
- Fundamental
- Price
- BXSL $29.81
- NUVL $76.04
- Analyst Decision
- BXSL Buy
- NUVL Strong Buy
- Analyst Count
- BXSL 5
- NUVL 10
- Target Price
- BXSL $31.25
- NUVL $119.60
- AVG Volume (30 Days)
- BXSL 967.8K
- NUVL 503.8K
- Earning Date
- BXSL 08-06-2025
- NUVL 08-07-2025
- Dividend Yield
- BXSL 10.34%
- NUVL N/A
- EPS Growth
- BXSL N/A
- NUVL N/A
- EPS
- BXSL 2.83
- NUVL N/A
- Revenue
- BXSL $1,398,444,000.00
- NUVL N/A
- Revenue This Year
- BXSL $9.58
- NUVL N/A
- Revenue Next Year
- BXSL $3.71
- NUVL N/A
- P/E Ratio
- BXSL $10.54
- NUVL N/A
- Revenue Growth
- BXSL 14.70
- NUVL N/A
- 52 Week Low
- BXSL $25.89
- NUVL $55.54
- 52 Week High
- BXSL $34.64
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- BXSL 30.06
- NUVL 44.51
- Support Level
- BXSL $29.85
- NUVL $71.13
- Resistance Level
- BXSL $30.69
- NUVL $79.00
- Average True Range (ATR)
- BXSL 0.47
- NUVL 2.98
- MACD
- BXSL -0.17
- NUVL -0.25
- Stochastic Oscillator
- BXSL 4.20
- NUVL 39.71
About BXSL Blackstone Secured Lending Fund of Beneficial Interest
Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.